Skip to main content
Erschienen in: Critical Care 1/2015

Open Access 01.12.2015 | Research

Hyperdynamic left ventricular ejection fraction in the intensive care unit

verfasst von: Joseph R. Paonessa, Thomas Brennan, Marco Pimentel, Daniel Steinhaus, Mengling Feng, Leo Anthony Celi

Erschienen in: Critical Care | Ausgabe 1/2015

Abstract

Introduction

Limited information exists on the etiology, prevalence, and significance of hyperdynamic left ventricular ejection fraction (HDLVEF) in the intensive care unit (ICU). Our aim in the present study was to compare characteristics and outcomes of patients with HDLVEF with those of patients with normal left ventricular ejection fraction in the ICU using a large, public, deidentified critical care database.

Methods

We conducted a longitudinal, single-center, retrospective cohort study of adult patients who underwent echocardiography during a medical or surgical ICU admission at the Beth Israel Deaconess Medical Center using the Multiparameter Intelligent Monitoring in Intensive Care II database. The final cohort had 2867 patients, of whom 324 had HDLVEF, defined as an ejection fraction >70 %. Patients with an ejection fraction <55 % were excluded.

Results

Compared with critically ill patients with normal left ventricular ejection fraction, the finding of HDLVEF in critically ill patients was associated with female sex, increased age, and the diagnoses of hypertension and cancer. Patients with HDLVEF had increased 28-day mortality compared with those with normal ejection fraction in multivariate logistic regression analysis adjusted for age, sex, Sequential Organ Failure Assessment score, Elixhauser score for comorbidities, vasopressor use, and mechanical ventilation use (odds ratio 1.38, 95 % confidence interval 1.039–1.842, p =0.02).

Conclusions

The presence of HDLVEF portended increased 28-day mortality, and may be helpful as a gravity marker for prognosis in patients admitted to the ICU. Further research is warranted to gain a better understanding of how these patients respond to common interventions in the ICU and to determine if pharmacologic modulation of HDLVEF improves outcomes.
Hinweise

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

JRP, TB, MP, MF, and LAC contributed substantially to the study design and methodology. JRP, TB, DS, and LAC assisted with data interpretation and the drafting of the initial manuscript. All authors read, edited, and approved the intellectual content of the final manuscript.

Authors’ information

JRP completed internal medicine residency at Beth Israel Deaconess Medical Center and is a Pulmonary and Critical Care fellow at Northwestern Memorial Hospital. TB completed his doctoral degree in engineering science at the University of Oxford with a focus on interdisciplinary approaches to cardiology research and currently specializes in physiological modeling and medical informatics at the Massachusetts Institute of Technology (MIT). MP is a doctoral candidate in biomedical signal processing at the University of Oxford. DS is in his third year of a cardiology fellowship at Beth Israel Deaconess Medical Center. MF is a senior postdoctoral fellow at MIT with a research focus on developing statistical causal inference and machine learning. LAC is a faculty member at Harvard Medical School, works as an intensivist at Beth Israel Deaconess Medical Center, and is the clinical research director at the Laboratory of Computational Physiology at MIT.
Abkürzungen
ACC
American College of Cardiology
CHF
congestive heart failure
CSRU
cardiac surgical resuscitation unit
DRG
Diagnosis-related group
EF
ejection fraction
HDLVEF
hyperdynamic left ventricular ejection fraction on echocardiogram
ICD-9
International Classification of Diseases–Ninth Revision
ICU
intensive care unit
IQR
interquartile range
IV
intravenous
LVEF
left ventricular ejection fraction
MAP
mean arterial pressure
MICU
medical intensive care unit
MIMIC II
Multiparameter Intelligent Monitoring in Intensive Care II, an ICU database
NLVEF
normal left ventricular ejection fraction on echocardiogram
SICU
surgical intensive care unit
SOFA
Sequential Organ Failure Assessment
TTE
transthoracic echocardiography
WBC
white blood cell count

Introduction

Hyperdynamic left ventricular ejection fraction (HDLVEF) on transthoracic echocardiography (TTE) is a frequent finding in the intensive care unit (ICU). The American College of Cardiology (ACC) defines HDLVEF as a left ventricular ejection fraction >70 % [1]. In spite of the growing use of TTE in the critical care setting, limited information exists on the etiology, prevalence, and significance of HDLVEF in the ICU.
Prior studies have suggested increased prevalence of HDLVEF in certain patient populations and disease processes. Patients with sepsis commonly have low systemic vascular resistance [2] and increased circulating catecholamines, leading to increased contractility [3], which could explain why patients with sepsis may develop HDLVEF. One study demonstrated that, in patients with septic shock, HDLVEF was more common in the subset of patients with concurrent cirrhosis [4]. Research has also suggested that HDLVEF in patients with non-traumatic shock is highly specific, but not sensitive, for sepsis [5]. Outside the diagnosis of sepsis, critically ill patients with HDLVEF have not been studied.
In the outpatient setting, female sex and obesity have been associated with a higher prevalence of HDLVEF without any clear mechanism [6, 7]. Furthermore, HDLVEF has not been shown to be associated with aerobic fitness [8], which suggests that HDLVEF may be due to a pathophysiologic response rather than to cardiovascular conditioning. These studies have provided some insight, but the significance of HDLVEF remains undefined.
There have not been any studies in which researchers compared outcomes of patients with HDLVEF with those of patients with normal left ventricular ejection fraction on an electrocardiogram (NLVEF). Using a large, public, deidentified critical care database, we studied the prevalence, characteristics, and outcomes of patients with HDLVEF in an ICU setting.

Materials and methods

We conducted a longitudinal, single-center, retrospective cohort study of adult patients who underwent TTE during an ICU admission at the Beth Israel Deaconess Medical Center. Data were extracted from the Multiparameter Intelligent Monitoring in Intensive Care II database (MIMIC II). MIMIC II is freely available in the public domain and contains information derived from the electronic medical records of 32,425 patients admitted to the ICUs at the Beth Israel Deaconess Medical Center between 2001 and 2008. Twenty-eight–day mortality information was obtained from Social Security Death Index records. The creation and use of the MIMIC II database for research was approved by the institutional review boards of both Beth Israel Deaconess Medical Center and the Massachusetts Institute of Technology (Institutional Review Board protocol 2001-P-001699/3). No further patient consent is required for use of this deidentified public database.
All adult patients in the database were screened. Data regarding age, sex, Sequential Organ Failure Assessment score (SOFA) [9], laboratory values, vital signs, diagnosis-related group (DRG) codes, and International Classification of Diseases–Ninth Revision (ICD-9) diagnoses were extracted. Medical comorbidities were represented by the Elixhauser score [10] for 30 comorbidities as calculated using the DRG and ICD-9 codes from the respective hospital admission. The worst values of common pertinent laboratory results were also extracted, including white blood cell count, lactate, and creatinine. Patients with sepsis were identified using the Angus criteria [11].
For patients with multiple ICU stays, the first ICU admission was used. Patients in the database were admitted to one of the following: medical ICU (MICU), surgical ICU (SICU), cardiac ICU, or cardiac surgical resuscitation unit. The study was limited to MICU and SICU patients to exclude elective admissions. Patients with at least one TTE were included in the cohort. HDLVEF was defined as an ejection fraction (EF) >70 % based on the ACC guidelines, and NLVEF was defined as an EF of 55–70 % [1]. Those with an EF <55 % were excluded from the analysis to minimize confounding of the relationship between HDLVEF and clinical outcomes. EF was determined predominately by visual estimation using two-dimensional imaging with incorporation of fractional shortening in the parasternal long-axis view according to guidelines established by the American Society of Echocardiography [12]. Contrast echocardiography was used when standard imaging was not diagnostic, and this method has been shown to reliably correlate with quantitative measurements [13]. To ensure the quality of using natural language processing for EF categorization, a random sample of 100 TTE reports was manually reviewed. This showed exceptionally high algorithm accuracy.
Baseline comparisons were performed using Fisher’s exact test for categorical variables, where counts and percentages were reported. Continuous variables were compared using a two-sample Wilcoxon rank-sum test, also known as the Mann–Whitney U test, and reported as median with interquartile range (IQR). Statistical significance was defined as p values <0.01 for the baseline characteristics shown in Table 1.
Table 1
Characteristics of patients with NLVEF compared with HDLVEF
 
NLVEF
HDLVEF
p Value
Age, yr
65 [51–78]
69 [56–78]
0.03
Male sex
1246 (49 %)
134 (41 %)
<0.01
MICU
1720 (68 %)
221 (68 %)
0.9
SICU
823 (32 %)
103 (32 %)
0.9
Time to echo (days)
1.1 [0.1–3.3]
0.9 [0.0–4.2]
0.4
Time to vasopressor use (days)
0.1 [0.0–0.5]
0.1 [0.0–0.7]
1.0
Comorbidities
 
 Diabetes mellitus
590 (23 %)
89 (27 %)
0.1
 Alcohol abuse
153 (6 %)
19 (6 %)
1.0
 Arrhythmias
700 (28 %)
82 (25 %)
0.4
 Valvular disease
255 (10 %)
38 (12 %)
0.3
 Hypertension
852 (34 %)
134 (41 %)
<0.01
 Renal failure
213 (8 %)
29 (9 %)
0.7
 Chronic pulmonary
536 (21 %)
68 (21 %)
1.0
 Liver disease
199 (8 %)
32 (10 %)
0.2
 Cancer
120 (5 %)
28 (9 %)
<0.01
 Psychosis
117 (5 %)
15 (5 %)
1.0
 Depression
148 (6 %)
12 (4 %)
0.1
 CHF
841 (33 %)
127 (39 %)
0.03
CHF congestive heart failure, HDLVEF hyperdynamic left ventricular ejection fraction on echocardiogram, MICU medical intensive care unit, NLVEF normal left ventricular ejection fraction on echocardiogram, SICU surgical intensive care unit
Characteristics of patients with NLVEF compared with HDLVEF are displayed as either n (%) or median [IQR]. p Values <0.01 are listed in bold
A multivariable logistic regression analysis was performed with 28-day mortality as the outcome. Covariates included age, sex, SOFA score, Elixhauser score of comorbidities, mechanical ventilation use, vasopressor use, and the presence of HDLVEF. Mechanical ventilation was represented as a binary variable. Since vasopressors have wide ranges of therapeutic intensity, sensitivity analyses were performed in the way vasopressor use was adjusted for. The analyses were adjusted for vasopressor use as a binary variable (yes or no), maximum number of vasopressors, or maximum vasopressor dose, defined as a fraction of the highest recommended dose for each vasopressor. The odds ratios (ORs) are preserved in the logistic regression model with 95 % confidence intervals (CIs). Two-sided p values <0.05 were considered statistically significant.

Results

Inclusion and exclusion criteria

As shown in Fig. 1, there were a total of 7253 patients with TTE. The study was limited to MICU and SICU patients to exclude elective admissions. The remaining cohort comprised 3851 patients with TTE. Per TTE reports, EF could not be estimated in 100 patients, owing to poor windows, body habitus or patient positioning. These patients were likewise excluded. Ultimately, 884 patients with depressed EF were removed. The final cohort comprised 2867 patients, of whom 324 had HDLVEF. The time to TTE was similar between the HDLVEF and NLVEF groups, with the median being approximately 1 day after arrival to ICU (Table 1).

Study outcome analysis

The distribution of MICU and SICU patients were similar in the groups with NLVEF and HDLVEF (Table 1). With respect to baseline characteristics, patients with HDLVEF were more likely to be older and female. Diagnoses associated with HDLVEF included hypertension and cancer, based on ICD-9 codes. There was a trend toward association with congestive heart failure (CHF) and sepsis, but it did not reach a p value <0.01. HDLVEF patients as a cohort also had a slightly higher SOFA score (7 [IQR 4–10] vs. 6 [IQR 3–9], p <0.01), suggesting increased acute disease severity. Tachycardia, lower mean arterial pressure, leukocytosis, and higher serum lactates were all more commonly seen in the HDLVEF cohort. HDLVEF patients were treated more frequently with vasopressors and mechanical ventilation, as shown in Table 2. Norepinephrine, phenylephrine, and dopamine were the most frequently used vasopressors in both groups, respectively. Dobutamine and epinephrine were rarely used in both groups, and levosimendan was not used in any of the patients (data not shown). Use of inotropes is much more common in the cardiac and cardiothoracic ICU patients, who were not included in this study.
In multivariate analysis, HDLVEF patients had increased 28-day mortality compared with patients with NLVEF (OR 1.38, 95 % CI 1.039–1.842, p =0.02) after adjusting for age, sex, SOFA score, Elixhauser score, mechanical ventilation, and vasopressor use (Table 3). All three methods of representation of vasopressor use in the sensitivity analysis did not alter the OR of the presence of HDLVEF in the multivariable logistic regression model (data not shown).
Table 2
Acute illness severity and treatments performed of patients with NLVEF compared with HDLVEF
 
NLVEF
HDLVEF
p value
Acute illness indicators
   
 SOFA score
6 [3–9]
7 [4–10]
<0.01
 Sepsis
1025 (40 %)
150 (46 %)
0.04
 Heart rate maximum, beats/min
113 [98–130]
120 [103–139]
<0.01
 MAP minimum, mmHg
56 [48–64]
52 [43–62]
<0.01
 Temperature maximum (°C)
37.8 [37.3–38.5]
37.9 [37.4–38.5]
0.6
Selected laboratory results
   
 WBC max k/μL
13.3 [9.4–18.3]
14.6 [10.2–20.5]
<0.01
 Lactate max mMol/L
2.1 [1.4–3.7]
2.6 [1.6–4.8]
<0.01
 Creat max mg/dL
1.1 [0.8–1.8]
1.2 [0.8–2.0]
0.04
Treatments received
   
 Renal replacement
288 (11 %)
50 (15 %)
0.04
 Vasopressor use
741 (29 %)
125 (39 %)
<0.01
 Mechanical ventilation
1298 (51 %)
198 (61 %)
<0.01
 IV fluids, L (first 24 h)
2.2 [0.6–5.2]
2.5 [0.7–5.7]
0.2
HDLVEF hyperdynamic left ventricular ejection fraction on echocardiogram, IV intravenous, MAP mean arterial pressure, NLVEF normal left ventricular ejection fraction on echocardiogram, SOFA Sequential Organ Failure Assessment, WBC white blood cell count
Acute illness severity and treatments performed for patients with NLVEF compared with HDLVEF are displayed as either n (%) or median [IQR]. p Values <0.01 are listed in bold
Table 3
Multivariable logistic regression model for 28-day mortality
 
Odds ratio (95 % confidence interval)
p value
Age
1.011 (1.007–1.016)
<0.001
Male sex
0.972 (0.792–1.192)
0.8
Elixhauser score
1.054 (1.037–1.071)
<0.001
SOFA score
1.128 (1.091–1.166)
<0.001
Mechanical ventilation
1.177 (0.906–1.530)
0.2
Vasopressor use
1.210 (0.943–1.549)
0.1
HDLVEF
1.389 (1.039–1.842)
0.02
HDLVEF hyperdynamic left ventricular ejection fraction on echocardiogram, SOFA Sequential Organ Failure Assessment
Multivariable logistic regression model for 28-day mortality in all patients. p Values <0.05 are listed in bold

Discussion

HDLVEF was present in 8.6 % of ICU patients who had a TTE during their ICU admission. The median time to TTE after arrival to the ICU was similar between groups (Table 1), which suggests that the presence of HDLVEF and its association with the outcome were not confounded by the timing of TTE.
The finding of HDLVEF was associated with female sex, increased age, and diagnoses of hypertension and cancer. There was a trend toward association with CHF and sepsis. In multivariate logistic regression analysis, patients with HDLVEF had increased 28-day mortality compared with those with NLVEF.
The exact cause of HDLVEF in the ICU is not well understood. Cardiac function is extremely variable in the setting of critical illness and depends on multiple physiologic determinants [3]. Cardiac systolic function is related to heart rate, preload, afterload, and contractility. A patient’s EF may be hyperdynamic in the setting of critical illness owing to changes in these basic physiologic parameters.
Prior research suggested that hypovolemia could lead to HDLVEF [14]. In contrast, a small study showed that three of four patients with HDLVEF on transesophageal echocardiography had pulmonary capillary wedge pressures >20 mmHg, which argues against hypovolemia as an etiology [15]. In our study, patients with NLVEF and HDLVEF received a similar amount of intravenous fluid in the first 24 h (Table 1), although this cannot exclude hypovolemia and decreased systemic vascular resistance as contributors to HDLVEF.
HDLVEF was also found to be associated with cancer. Many studies have shown increased cytokine levels in patients with various types of cancer [1619], which may explain the presence of HDLVEF among critically ill patients with cancer.
It is unclear if diastolic dysfunction contributes to the development of HDLVEF. It is plausible that patients with diastolic dysfunction are more likely to develop HDLVEF, either chronically or in the setting of acute illness, to compensate for the reduced preload from impaired relaxation during ventricular filling. Another mechanism could be increased circulating cytokines within the tumor necrosis factor α axis, which has been suggested to be a contributor to the development of CHF with preserved EF [20]. Several other biomarkers of myocyte stress, inflammation, and extracellular matrix remodeling have been shown to be associated with CHF with preserved EF [21]. It is unknown if this may be seen in HDLVEF as well. Alternatively, mismatch of myocardial contractility and arterial compliance may be present in patients with HDLVEF, which might explain the trend toward development of CHF. The presence of ventriculoarterial decoupling, defined as the ratio of the arterial elastance to the ventricular elastance, can be found in many disease states and may lead to worse outcomes [22]. These inferences cannot be deduced from our analysis and should be investigated further.
As anticipated based on a literature review, we found that HDLVEF is more frequently seen with a diagnosis of sepsis. Adequately resuscitated patients with severe sepsis can have warm peripheries, high cardiac output, and HDLVEF [23]. Despite a prior study suggesting that HDLVEF was highly specific for sepsis, our study showed that HDLVEF was seen frequently outside the diagnosis of sepsis. It is also important to note that EF may be depressed in sepsis, as has been demonstrated in prior studies [19, 2428]. The information in the literature is mixed with regard to EF and prognosis in patients with sepsis [29, 30]. In addition to systolic dysfunction, diastolic dysfunction has been described in sepsis [26, 27]. It might contribute to the development of HDLVEF, though this present study was not designed for such an investigation.

Limitations

Our study is limited by its retrospective nature and its inclusion of a relatively heterogeneous group of patients whose data were extracted from electronic medical records in a large clinical database. Other variables not captured in the database may account for residual confounding. Disease associations such as hypertension and cancer are based on ICD-9 codes, which can lead to inconsistent levels of reporting, but this may be somewhat mitigated by the single-center scope of the study. The indications for TTE could be variable and could not be accounted for in this study. Common reasons for TTE in our institution include workup for hypotension and heart failure and evaluation for bacterial endocarditis or right heart strain owing to acute pulmonary embolism. In this study, the need for TTE was at the discretion of the ordering physicians. The indication was not documented.
Bias might have been introduced by excluding patients without TTE during their ICU admission. We compared patients who had TTE to those without TTE with respect to the parameters listed in Table 1, in addition to mortality data. On the basis of this additional analysis, we found that the patients who did not undergo TTE were younger, had fewer comorbidities, were less sick (based on SOFA scores, vital signs, laboratory results, use of vasopressors, and mechanical ventilation), and had better outcomes (data not shown) than other patients. This makes sense from a clinical standpoint—the physicians did not feel that additional information provided by TTE was necessary to manage these patients. These patients who were excluded because they did not undergo TTE look more similar to those patients with NLVEF than to those with HDLVEF. If most of the excluded patients indeed had NLVEF, their inclusion into the analysis, assuming that they had NLVEF, would likely have increased the effect size, given their better outcomes.

Implications

To our knowledge, this study is the first large-scale evaluation of HDLVEF in the ICU setting. It is difficult to determine exactly why HDLVEF has a worse prognosis when seen during critical illness. The etiology of increased mortality in the HDLVEF group may be related to the myocardial mechanics of HDLVEF, or it could be a marker or proxy of a pathophysiologic process. The presence of HDLVEF, in addition to traditional mortality risk predictors, may provide additional prognostic implications for ICU patients.

Further research

HDLVEF patients may respond differently to common interventions such as fluid administration, vasopressor use, and mechanical ventilation. If cardiovascular mechanics are the etiology of worse prognosis, then further studies might be considered to investigate whether modulating HDLVEF with pharmacotherapy improves outcomes. Interestingly, β-blockade has been shown to decrease mortality in patients with severe septic shock [31]. If catecholamine surge is the etiology of HDLVEF, closely monitored β-blockade might be examined to attenuate the HDLVEF. Similarly, the trend toward association between CHF and HDLVEF is interesting and warrants further investigation.

Conclusions

Compared with critically ill patients with NLVEF, the finding of HDLVEF in critically ill patients was associated with female sex, increased age, and diagnoses of hypertension and cancer. Patients with HDLVEF had increased 28-day mortality compared with those with normal EF in multivariate logistic regression analysis adjusting for age, sex, SOFA score, Elixhauser score of comorbidities, vasopressor use, and mechanical ventilation use. The presence of HDLVEF portended increased 28-day mortality and may be helpful as a gravity marker for prognosis of patients admitted to the ICU. Further research is warranted to better understand how these patients respond to common interventions in the ICU and to determine if pharmacologic modulation of HDLVEF improves outcomes.

Key messages

  • HDLVEF prevalence was 8.6 % in ICU patients who underwent TTE during their ICU admission.
  • HDLVEF in the ICU has not been well described in the literature, especially on a large scale.
  • The finding of HDLVEF was associated with female sex, increased age, hypertension, and cancer.
  • Patients with HDLVEF were sicker and had increased adjusted 28-day mortality compared with the other patients.
  • Further research is warranted to better understand how HDLVEF patients respond to common interventions in the ICU.

Acknowledgments

We acknowledge all of those involved in the design, construction, and maintenance of the open access MIMIC II database at the MIT Laboratory of Computational Physiology. LAC is funded by the National Institutes of Health (NIH) through National Institute of Biomedical Imaging and Bioengineering grant R01 EB017205-01A1. No other authors received funding. None of the authors has a financial conflict of interest pertaining to this study, but our laboratory at MIT receives funding from the NIH and Philips Healthcare. The NIH and Philips Healthcare did not have any role in the design, collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

JRP, TB, MP, MF, and LAC contributed substantially to the study design and methodology. JRP, TB, DS, and LAC assisted with data interpretation and the drafting of the initial manuscript. All authors read, edited, and approved the intellectual content of the final manuscript.

Authors’ information

JRP completed internal medicine residency at Beth Israel Deaconess Medical Center and is a Pulmonary and Critical Care fellow at Northwestern Memorial Hospital. TB completed his doctoral degree in engineering science at the University of Oxford with a focus on interdisciplinary approaches to cardiology research and currently specializes in physiological modeling and medical informatics at the Massachusetts Institute of Technology (MIT). MP is a doctoral candidate in biomedical signal processing at the University of Oxford. DS is in his third year of a cardiology fellowship at Beth Israel Deaconess Medical Center. MF is a senior postdoctoral fellow at MIT with a research focus on developing statistical causal inference and machine learning. LAC is a faculty member at Harvard Medical School, works as an intensivist at Beth Israel Deaconess Medical Center, and is the clinical research director at the Laboratory of Computational Physiology at MIT.
Literatur
2.
Zurück zum Zitat Groeneveld ABJ, Nauta JJ, Thijs L. Peripheral vascular resistance in septic shock: its relation to outcome. Intensive Care Med. 1988;14:141–7.CrossRef Groeneveld ABJ, Nauta JJ, Thijs L. Peripheral vascular resistance in septic shock: its relation to outcome. Intensive Care Med. 1988;14:141–7.CrossRef
3.
Zurück zum Zitat Vieillard-Baron A, Prin S, Chergui K, Dubourg O, Jardin F. Hemodynamic instability in sepsis: bedside assessment by Doppler echocardiography. Am J Respir Crit Care Med. 2003;168:1270–6.CrossRef Vieillard-Baron A, Prin S, Chergui K, Dubourg O, Jardin F. Hemodynamic instability in sepsis: bedside assessment by Doppler echocardiography. Am J Respir Crit Care Med. 2003;168:1270–6.CrossRef
4.
Zurück zum Zitat Thierry S, Giroux Leprieur E, Lecuyer L, Brocas E, Van de Louw A. Echocardiographic features, mortality, and adrenal function in patients with cirrhosis and septic shock. Acta Anaesthesiol Scand. 2008;52:45–51.CrossRef Thierry S, Giroux Leprieur E, Lecuyer L, Brocas E, Van de Louw A. Echocardiographic features, mortality, and adrenal function in patients with cirrhosis and septic shock. Acta Anaesthesiol Scand. 2008;52:45–51.CrossRef
5.
Zurück zum Zitat Jones AE, Craddock PA, Tayal VS, Kline JA. Diagnostic accuracy of left ventricular function for identifying sepsis among emergency department patients with nontraumatic symptomatic undifferentiated hypotension. Shock. 2005;24:513–7.CrossRef Jones AE, Craddock PA, Tayal VS, Kline JA. Diagnostic accuracy of left ventricular function for identifying sepsis among emergency department patients with nontraumatic symptomatic undifferentiated hypotension. Shock. 2005;24:513–7.CrossRef
6.
Zurück zum Zitat Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Di Mario U, Leonetti F. Adapted changes in left ventricular structure and function in severe uncomplicated obesity. Obes Res. 2004;12:1616–21.CrossRef Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Di Mario U, Leonetti F. Adapted changes in left ventricular structure and function in severe uncomplicated obesity. Obes Res. 2004;12:1616–21.CrossRef
7.
Zurück zum Zitat Buonanno C, Arbustini E, Rossi L, Dander B, Vassanelli C, Paris B, et al. Left ventricular function in men and women: another difference between sexes. Eur Heart J. 1982;3:525–8.CrossRef Buonanno C, Arbustini E, Rossi L, Dander B, Vassanelli C, Paris B, et al. Left ventricular function in men and women: another difference between sexes. Eur Heart J. 1982;3:525–8.CrossRef
8.
Zurück zum Zitat Abernethy WB, Choo JK, Hutter Jr AM. Echocardiographic characteristics of professional football players. J Am Coll Cardiol. 2003;41:280–4.CrossRef Abernethy WB, Choo JK, Hutter Jr AM. Echocardiographic characteristics of professional football players. J Am Coll Cardiol. 2003;41:280–4.CrossRef
9.
Zurück zum Zitat Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;26:707–10.CrossRef Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;26:707–10.CrossRef
10.
Zurück zum Zitat Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.CrossRef Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.CrossRef
11.
Zurück zum Zitat Linde-Zwirble WT, Angus DC. Severe sepsis epidemiology: sampling, selection, and society. Crit Care. 2004;8:222–6.CrossRef Linde-Zwirble WT, Angus DC. Severe sepsis epidemiology: sampling, selection, and society. Crit Care. 2004;8:222–6.CrossRef
12.
Zurück zum Zitat Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358–67.CrossRef Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358–67.CrossRef
13.
Zurück zum Zitat Bergenzaun L, Gudmundsson P, Ohlin H, Düring J, Ersson A, Ihrman L, et al. Assessing left ventricular systolic function in shock: evaluation of echocardiographic parameters in intensive care. Crit Care. 2011;15:R200.CrossRef Bergenzaun L, Gudmundsson P, Ohlin H, Düring J, Ersson A, Ihrman L, et al. Assessing left ventricular systolic function in shock: evaluation of echocardiographic parameters in intensive care. Crit Care. 2011;15:R200.CrossRef
14.
Zurück zum Zitat Alberti C, Brun-Buisson C, Chevret S, Antonelli M, Goodman SV, Martin C, et al. Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med. 2005;171:461–8.CrossRef Alberti C, Brun-Buisson C, Chevret S, Antonelli M, Goodman SV, Martin C, et al. Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med. 2005;171:461–8.CrossRef
15.
Zurück zum Zitat Beaulieu Y, Marik PE. Bedside ultrasonography in the ICU: part 1. Chest. 2005;128:881–95.CrossRef Beaulieu Y, Marik PE. Bedside ultrasonography in the ICU: part 1. Chest. 2005;128:881–95.CrossRef
16.
Zurück zum Zitat Kim YW, Kim SK, Kim CS, Kim IY, Cho MY, Kim NK. Association of serum and intratumoral cytokine profiles with tumor stage and neutrophil lymphocyte ratio in colorectal cancer. Anticancer Res. 2014;34:3481–7.PubMed Kim YW, Kim SK, Kim CS, Kim IY, Cho MY, Kim NK. Association of serum and intratumoral cytokine profiles with tumor stage and neutrophil lymphocyte ratio in colorectal cancer. Anticancer Res. 2014;34:3481–7.PubMed
17.
Zurück zum Zitat Rutkowski P, Kamińska J, Kowalska M, Ruka W, Steffen J. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol. 2003;84:151–9.CrossRef Rutkowski P, Kamińska J, Kowalska M, Ruka W, Steffen J. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol. 2003;84:151–9.CrossRef
18.
Zurück zum Zitat Reers S, Pfannerstill AC, Rades D, Maushagen R, Andratschke M, Pries R, et al. Cytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer. Anticancer Res. 2013;33:2481–9.PubMed Reers S, Pfannerstill AC, Rades D, Maushagen R, Andratschke M, Pries R, et al. Cytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer. Anticancer Res. 2013;33:2481–9.PubMed
19.
Zurück zum Zitat Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E, et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis: M-CSF – an independent prognostic factor. Oncology. 2006;70:115–25.CrossRef Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E, et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis: M-CSF – an independent prognostic factor. Oncology. 2006;70:115–25.CrossRef
20.
Zurück zum Zitat Putko BN, Wang Z, Lo J, Anderson T, Becher H, Dyck JR, et al. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology. PLoS One. 2014;9:e99495.CrossRef Putko BN, Wang Z, Lo J, Anderson T, Becher H, Dyck JR, et al. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology. PLoS One. 2014;9:e99495.CrossRef
21.
Zurück zum Zitat Cheng JM, Akkerhuis KM, Battes LC, van Vark LC, Hillege HL, Paulus WJ, et al. Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail. 2013;15:1350–62.CrossRef Cheng JM, Akkerhuis KM, Battes LC, van Vark LC, Hillege HL, Paulus WJ, et al. Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail. 2013;15:1350–62.CrossRef
22.
Zurück zum Zitat Guarracino F, Baldassarri R, Pinsky MR. Ventriculo-arterial decoupling in acutely altered hemodynamic states. Crit Care. 2013;17:213.CrossRef Guarracino F, Baldassarri R, Pinsky MR. Ventriculo-arterial decoupling in acutely altered hemodynamic states. Crit Care. 2013;17:213.CrossRef
23.
Zurück zum Zitat Flynn A, Chokkalingram M, Mather P. Sepsis-induced cardiomyopathy: a review of pathophysiologic mechanisms. Heart Fail Rev. 2010;15:605–11.CrossRef Flynn A, Chokkalingram M, Mather P. Sepsis-induced cardiomyopathy: a review of pathophysiologic mechanisms. Heart Fail Rev. 2010;15:605–11.CrossRef
24.
Zurück zum Zitat Kumar A, Bunnell E, Lynn M, Anel R, Habet K, Neumann A, et al. Experimental human endotoxemia is associated with depression of load-independent contractility indices: prevention by the lipid A analogue E5531. Chest. 2004;126:860–7.CrossRef Kumar A, Bunnell E, Lynn M, Anel R, Habet K, Neumann A, et al. Experimental human endotoxemia is associated with depression of load-independent contractility indices: prevention by the lipid A analogue E5531. Chest. 2004;126:860–7.CrossRef
25.
Zurück zum Zitat Krishnagopalan S, Kumar A, Parrillo JE, Kumar A. Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care. 2002;8:376–88.CrossRef Krishnagopalan S, Kumar A, Parrillo JE, Kumar A. Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care. 2002;8:376–88.CrossRef
26.
Zurück zum Zitat Vieillard-Baron A, Cecconi M. Understanding cardiac failure in sepsis. Intensive Care Med. 2014;40:1560–3.CrossRef Vieillard-Baron A, Cecconi M. Understanding cardiac failure in sepsis. Intensive Care Med. 2014;40:1560–3.CrossRef
27.
Zurück zum Zitat Thijs LG, Schneider AJ, Groeneveld ABJ. The haemodynamics of septic shock. Intensive Care Med. 1990;16:S182–6.CrossRef Thijs LG, Schneider AJ, Groeneveld ABJ. The haemodynamics of septic shock. Intensive Care Med. 1990;16:S182–6.CrossRef
28.
Zurück zum Zitat Shah AM, Grocott-Mason RM. Cardiac dysfunction in sepsis: new theories and clinical implications. Intensive Care Med. 1998;24:286–95.CrossRef Shah AM, Grocott-Mason RM. Cardiac dysfunction in sepsis: new theories and clinical implications. Intensive Care Med. 1998;24:286–95.CrossRef
29.
Zurück zum Zitat Huang SJ, Nalos M, McLean AS. Is early ventricular dysfunction or dilatation associated with lower mortality rate in adult severe sepsis and septic shock? A Meta-Analysis Crit Care. 2013;17:R96.PubMed Huang SJ, Nalos M, McLean AS. Is early ventricular dysfunction or dilatation associated with lower mortality rate in adult severe sepsis and septic shock? A Meta-Analysis Crit Care. 2013;17:R96.PubMed
30.
Zurück zum Zitat Repessé X, Charron C, Vieillard-Baron A. Evaluation of left ventricular systolic function revisited in septic shock. Crit Care. 2013;17:164.CrossRef Repessé X, Charron C, Vieillard-Baron A. Evaluation of left ventricular systolic function revisited in septic shock. Crit Care. 2013;17:164.CrossRef
31.
Zurück zum Zitat Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310:1683–91.CrossRef Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310:1683–91.CrossRef
Metadaten
Titel
Hyperdynamic left ventricular ejection fraction in the intensive care unit
verfasst von
Joseph R. Paonessa
Thomas Brennan
Marco Pimentel
Daniel Steinhaus
Mengling Feng
Leo Anthony Celi
Publikationsdatum
01.12.2015
Verlag
BioMed Central
Erschienen in
Critical Care / Ausgabe 1/2015
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-015-1012-8

Weitere Artikel der Ausgabe 1/2015

Critical Care 1/2015 Zur Ausgabe

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.